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Summary
A review of medical charts of all deaths for one year at a general
acute care hospital reveals that 135/602 (22%) charts indicate that
the patient had an advance directive. In 68/135 (50%) of the cases,
the patients were unable to participate in decisions and met the
conditions of the advance directive. In 33/68 (49%) of those cases
the records indicate that the advance directive influenced care. In 63
of the 135 charts the advance directive was present and chart
notations indicate an additional 25 advance directives were located
at the physician’s office. Eighteen of a total of 44 physicians listed
as attending accounted for the 33 cases in which the record indicates
that the advance directive was recognized. Twelve of these 135
patients were coded during their hospitalization. Three of the 12
were coded in the ER upon admission, the remaining 9 were coded
in the course of their care in the acute care hospital. Regarding code
status a three tiered (Cat I,Ji, III) classification system was in place.
Initial classification of the 135 patients upon admission was: 64
“full code” (I), 56 were “all but CPR” (II), 15 were “No code” (III).
Code classification at the time of death (or discharge) was: I =45,
11=53, 111=36.
Objective—To investigate the extent to which advance directives
influence clinical care of patients during the final acute hospitaliza
tions.
Design.—Retrospective chart review.
Setting.—General Hospital of 274 beds.
Patients.—602 death charts reviewed, 135 contained indications or
the execution of an advance directive.
Main Outcome Measures.—The 1995 medical records of 602
deaths were reviewed for evidence of influence of advance direc
tives in clinical care.
Results.—24% of patients who had advance directives in the chart
or at the physicians office had their directives recognized during
their final hospitalization. In 68/135 (50%) of the cases the condi
tions to activate the advance directive were met. And in 33/68(49%)
of those cases the advanced directive was invoked. There was some,
but less than expected correlation between advanced directives and
DNR orders. In a three tiered Code Category Classification system
(Cat. I, full code, Cat. II Chemical Code, Cat. III, No Code.) the
initial classifications in the 135 cases with evidence of advance
directives were Cat. 147%, Cat. 1142%, and Cat. III 11%. Compared
to 59 cases where there was no indication of an advance directive the
classifications were Cat. I 67%, Cat. II 26% and Cat. III 7 %.
However, the classifications in the two groups at the time of death
of the patients were Cat. 134% & 31%, Cat. 1139% & 39% and Cat.
11127% & 30%. There was a 20% increased incidence of an initial
classification of full code in the cases without indication of an
advance directive. But once the patient care involved review ofcode
status, the final classifications ofpatients were the same irrespective
of the presence of an advance directive.
Conclusions.—In 50% or 68/135 of the cases the patient met the
conditions for invocation of the advance directive and in 33 or 49%
of those cases the advance directive was invoked. Another way to
state the impact of advance directives in the population studied is
that in 22% of the 602 deaths there was indication of an advance
directive and in 50% of those cases the directive became relevant
and in 49% of those cases it had a bearing on the care (or in 5% of
the 602 deaths studied). More research is needed to determine why
advance directives are not utilized more and why they to do not have
greater effect on clinical care decisions in terminal patients. But
problems with making them available to relevant parties, hospital
record keeping, and physician recognition of their significance are
evident.
Introduction
Our society affirms the right of self-determination in health care
decisions. Competent patients can extend their right to when they
have lost decisional capacity through the use of advance directives
(i.e., livings wills or L.W. durable powers of attorney for health care
or DPA). In 1991 a nationwide Gallup poll reported that 75% of
Americans approved of living wills and by 1994 all states and the
District of Columbia had legislation recognizing some type of
advance directive. Advance directives have been identified and
promoted as instruments which can best ensure that one’s wishes
regarding medical treatment will be followed after one has lost
decisional capacity.’5They have gained favor because they pro
mote self-determination, are a guard against unwanted and often
futile medical interventions that only prolong the dying process, and
they relieve anxiety about loss of control and the burdens that fall on
others during a final hospitalization. This study suggests that despite
legislation which give advance directives standing as a legal means
for patients to provide health care decision makers with an expres
sion of their wishes, their performative force is recognized much
less than thought. ‘
While advance directives have been promoted as the patient’s best
instrument to ensure congruence between their wishes and the
aggressiveness of care at the end of the patient’s life, recently there
have been indications that they are not as efficacious as thought.64
This study explores the efficacy of advance directives in a general
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acute care hospital in 1995. In 1990 the Patient Self-determination
Act was implemented with the intent to identify patients entering
acute or long term care facilities who had executed an advance
directive and to encourage competent adults who had not to do so.’3
The completion of an advance directive is only the first step, which
by itself will do little to ensure that a patient’s wishes will have a
bearing on clinical practice. Advance directives are a form of
communication, and as such, they can fail in innumerable ways.
They not only must be executed, placed in the hands of the relevant
parties in order to be recognized, honored and have an affect on
clinical practice, but also, the conditions which they describe must
obtain in order for them to be invoked. Our study indicates that in
only 5% of the patients who died in 1995 at the hospital studied had
an advance directive which affected their care.
Methods
The medical charts ofall patients who died in 1995 from a 274 bed
general acute care hospital were reviewed for indication of a
previously executed advance directive. The author reviewed a total
of 602 death charts. The charts were reviewed to determine whether
there was any indication of a previously executed advance directive.
If no indication of an advance directive was found in the most recent
admission, the previous admissions up to one year were reviewed
for any indications of an advance directive. Indications of an
advance directive were found in 135 charts. Those charts were
reviewed further for demographic data, diagnosis upon admission,
type of admission, length of stay, cause of death, whether Coded,
Code Category, presence of advance directive(s), type of advance
directive(s), any notation about the advance directive (i.e., nurse,
physician, social worker), any notation indicating the patient’s
capacity to make decisions, physician(s), and number and type of
consultations. A member of the medical records department also
reviewed 28/135 charts to check for accuracy and verify the data
collected. (Tana Basa, R.N., Medical Records Clerk)
The criteria used to determine whether and to what extent advance
directives influenced the course of care included: 1) chart progress
notes documenting discussions between designated proxies and
physicians regarding treatment, 2) chart progress notes and consent
forms documenting consent by designated proxies for tests and
procedures, 3) chart notes regarding discussion of “Code status”
(DNR) with designated proxies , 4) chart notes regarding decisions
to withhold or withdraw care, 5) any reference in the chart to an
advance directive, including remarks by consultants, social work
ers, nurses notes, etc.. 6) certification that the patient’s condition
met the conditions described in the advance directive (as required by
the law). The meeting of any one of these was considered evidence
that the advanced directive influenced treatment decisions.
Demographic data was obtained from the charts regarding patient
age, gender, marital status, ethnicity, and type of advance directive
(living will or durable power of attorney). The patient’s admitting
diagnosis, diagnoses at death, type of admission (emergency or
elective), length of stay, code category classification, performance
of cardiopulmonary resuscitation, and number of physicians in
volved in the case (consultants) was also obtained.
Results
Of the 602 death charts for 1995 there was indication that an
advance directive (AD) was executed in 135 cases. Indication that
the patient had an advance directive was found in a variety of places
in the chart and in most cases there were multiple indications. Every
possible combination of the following indicators was found: 1) two
entries on the cover (face) sheet which indicates yes/no whether the
patient has a durable powers of attorney (DPA) and whether the
patient has a living will (LW), 2) the admission or intake sheet (Ad
1) addresses whether the patient has an advance directive, if yes,
what type, and it asks for the location, 3) the chart cover may have
had a florescent orange sticker, in a few cases the cover sheet had a
sticker, 4) the advance directive was in the file. See Table #1.
The most common situation was the intake sheet would say “yes”
and the advance directive was in the chart. Second most common,
only the intake sheet would say “yes” and no other indication of an
advance directive was found. As I indicated every possible combi
nation of circumstances was found except one (no case where the
only indication of an advance directive was an orange sticker).
Several charts were found with an orange sticker but no advance
directive. One conclusion to draw from such disparate empirical
data is that unless one was searching for an indication of the
execution ofan advance directive it could easily be overlooked. This
is because the cover sheet, the most evident document, was the least
reliable indicator. It indicated an advance directive in only 13% of
the cases that had other indications of the execution of an advance
directive. The intake sheet, on the other hand was reliable 61% of the
time, but this form is buried deep in the chart, has little relevance to
patient care, and is rarely looked at. The orange sticker was found
on 43 of the 63 charts where an advance directive was present and
on 4 in which there was no advance directive. The advance directive
was present in 63 charts but it was not displayed in the appropriate
place (prominently on the top left side) in 14 of those records (22%).
It should also be noted that 6 general powers of attorney were
mistakenly identified in the record as advance directives for health
care decisions.
Interviews were conducted with hospital staff from Medical
Records, Admission Intake interviewers, and nursing supervisors in
order to understand the generation, development deployment and
utilization of medical charts (how they are compiled, arranged,
managed, and provide for the trained eye - case histories) . The
charts in the medical records archives are what is left of the “hard
empirical record” and one sees very quickly the need for caution (or
Table 1.— Documentation of previously executed advance directive in
hospital charts of 135 cases where some indicator was
positive*
Yes NO
AD present in chart 63 72
Florescent Orange Sticker 45 90
CoverSheet 22 113
Admitting Form Ad1 ** 82 14
Present in chart With Family in MD Office
10 25 25
‘Most cases had multiple indicators of the previous execution of an advance directive.
“Some of the intake sheets indicated the presence of an advanced directive in the
chart, but it was not present.
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at least reserve) in the inferences we make based only on the records.
Demographic data regarding the patient age, gender, ethnicity,
and type of advance directive in those cases where the chart
indicated that the patient had a directive is found on Table 2. The
average age of the patients with indication of an advance directive
was 77 years (range, 38 to 102). 57% of the patients with advance
directives were male and 79% were either Japanese-Americans or
Caucasians. The living will was most common form of advance
directive (present in 60% of the cases). Whereas 12% had a durable
power of attorney for health care only, and 27% had executed both
a living will and a durable power of attorney.
Much of the information found on Table 3 gives an indication of
the seriousness of the patient’s health problems. The diagnosis of
patients at admission and the cause of death were invariably mul
tiple. Most patients had three or more problems and retrospectively
we know 115/135 (85%) died during or within 30 days of their last
hospitalization. Hospitalizations lasting two weeks or less consti
tuted 67% of the cases with nearly 50% of patients dying within one
week.
The code classification of these patients is of interest given that
they all have indications of execution of advance directives and
have serious multiple system disease. Briefly, the classification
system can be identified as follows: category I = “full code”,
category II = “chemical code” or all but CPR, category III = “no
code”. If the physician does not place a patient in a category, the
patient is a category I by default. In 47% of the cases patients were
initially “full code” by default while at the time of death 34%
remained “full code”. In these cases where the patient remained full
code, it was not possible from the record to determine whether the
code status was ever addressed by the physician. The majority of
classification changes from category Ito category II or III took place
within a day of the patient’s death. At the time of death 73% of these
patients would, according to hospital policy, have had a “code”
called if the classifications were adhered to and they had arrested in
the presence of hospital staff . This information raises questions
about the timeliness of addressing code classification in these cases
of patients with advance directives. When compared to a group of
59 cases where there was no evidence of an advance directive there
was a significant difference in the initial classification of category
I 67%, but the classifications at the time of death were virtually the
same as the group with advance directives.
Twelve of the 135 were coded, 3 in the ER and the other 9 during
their hospitalization. In three of the 9 cases where the patient was
coded during their hospitalization the advance directive was present
in the chart and in two of those cases the patient was coded more than
once.
Table 4 reveals that there was a 20% decrease in the incidence of
an initial full code classification in the cases with an indication of the
execution of an advance directive. If the directive was present in the
record the decrease was 27% and in those cases where the advance
directive was invoked the decrease in initial full code classification
was 55%. As seen in this data there is a relationship between
advance directives and the initial code classification. The more
evident the advance directive is the less likely that the patient will
have a initial code classification of “full code”. However, when one
looks at code status at the time of death (Table 5) there is no
significant difference in the classifications in any of the groups
except for the 33 cases where the physicians has explicitly invoked
Table 2.— Characteristics of 135 patients who had previously executed
an advance directive
Gender
Male
Female
Ethnicity
Number Percent
77 57%
59 43%
Table 3.—Clinical Information about 135 patients with documentation
of prior execution of an advance directive
Type of Admission
Diagnosis
Emergency
9
47 35%
60 44%
7 5%
2 1%
9 7%
11 26%
Elective/Acute
126
At Admission
Caucasian
Japanese.American
Filipino
Hawaiian
Portuguese
Undetermined
Age (years)
60 <
60 74
75 -84
85
unknown
Type of Advance Directive
Living Will only
Durable Power of Attorney only
Both LW and DPA
Other’
*These were cases of Jehovah’s Witnesses’ Medical Directive
Cause of Death
8
49
44
35
6%
35%
33%
26%
Cardiopulmonary disease
Respiratory disease
Digestive system disease
Malignant neoplasm (Cancer)
Renal disease
Sepsis, infection, pneumonia
Stroke, Brain Bleed, Coma
Diabetic Complications
Did not die in hospital (Other)
Length of Stay
0-7
44 33%
21 16%
15 11%
46 34%
32 24%
25 19%
27 20%
15 11%
na
40 30%
16 12%
9 6%
27 20%
20 15%
20 15%
18 13%
7 5%
35 26%
80 60%
16 12%
37 27%
8-14
15-30
63
30
26
Other’
23
8
Cardiopulmonary resuscitation performed
15
Yes No
12 123
Number of physicians and consultants involved (data from 64 cases)
1-2 33 51%
3.4 15 24%
>4 16 25%
Code Category
Category I
Category II
Category Ill
First classification
64 47%
56 42%
14 11%
Patient Died
Classification at time of death
45 34%
53 39%
36 27%
at home
35
in hospital
100
* cases where death was 30+ days after discharge and/or date of death cannot be
determined from the chart.
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Code category
Category I
“full code’
Category II
“chemical code”
Table 4.— Initial code classification in five different groups of cases.
the advanced directive.
Based on the information in the charts, 67/135 patients who had
previously executed an advance directive never reached a condition
where their advance directive could be invoked. These patients were
either competent, did not die in the hospital, or died in the ER and
thereby the initial conditions of the advance directive were not met
and hence it was proper that it was not invoked. In the remaining 68
cases these patients reached a point during their care where they did
not have decisional capacity and met the conditions of their advance
directives. In 33/68 or 48% of cases where the patient could not
participate in health care decisions, the record indicated that the
advance directives were recognized and influenced care. In 35/68
(52%) of these cases there was no indication that the advance
directive was recognized. The records in these cases document
consent of family members for invasive diagnostic or therapeutic
procedures, code classification, family conferences regarding care
plans, and withholding or withdrawal of medical care. In all these
cases decision making was not by the patient’s officially appointed
proxy and/or did not refer to the living will despite the fact that the
conditions of which the advanced directive presumably had been
fulfilled. These cases included aggressive care which was not in
accord with the advance directives including (CPR, tube feeding,
surgery, etc.). In the 33/68 (48%) of the cases without decisional
capacity the charts contained documentation recognizing the ad
vance directives, appointed proxies were referred to in notes, and
references were made to family conferences. However, of note is
that fact that in none of these 33 cases did the chart contain the
legislatively required certification by two physicians thatthe patient’s
condition met the activating conditions of the advance directive.
Commentary
This study raises serious questions about
the efficacy of advance directives as a way
to influence clinical care. Even when pa
tients lose decisional capacity there remains
the following problems: will the advance
directive be in the chart? If so, will it be in
the correct place, or recognized for what it
is? If acknowledged will the conditions de
scribed match the patient’s condition? Will
doctors take the advance directive seriously
even if all conditions are met? Or will they
instead be concerned primarily with the
views and wishes of family members? In
discussions with physicians about this study
we find that most take the views of the
family members to be more relevant than
advance directives. The behavior of most
physicians involved in the study suggests
that they are unlikely to consider the rel
evance of the advance directive unless they
are asked to by family members. Despite
their legal standing it is the rare physician in
this study who will follow an advance direc
tive if it is not in accord with the view of
family members. Ethically and legally such
a position is indefensible, however prag
matically the lesson is that those who want there advance directive
to direct clinical care must take pains to obtain family and physician
support of their directives.
Even if the many problems concerning availability and accuracy
of advance directives in patient records were overcome and physi
cians took a more supportive view about advance directives, in 50%
of the cases the advance directive would not have a bearing on
clinical decisions. So then, when we realize that only 24% of this
population had evidence of advance directives and only half of them
would under optimum conditions have had a bearing on care, claims
for the value of advance directives seem over stated.
59 cases with 135 cases with 53 cases with 83 cases with 33 cases where
no indication indication of AD indication of AD AD present the AD was
of AD at all but not present invoked
67% 47% 58% 40% 12%
26% 42% 36% 46% 67%
Category Ill 7% 11% 6% 14% 21%
“no code”
Table 5.—Code classification at death in five different groups of cases.
Code category 59 cases with 135 cases with 53 cases with 83 cases with 33 cases where
no indication indication of AD indication of AD AD present the AD was
of AD at all but not present invoked
Category I 31% 34% 39% 31% 3%
“full code”
Category II 39% 39% 37% 40% 55%
“chemical code”
Category III 30% 27% 24% 29% 42%
“no code”
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